UNSPSC 51131661: Drotrecogin alfa

This classification denotes an anticoagulant agent with the molecular formula C1786H2779N509O519S29, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JGH8MYC891, chemically known as recombinant human activated protein c but generally known as Drotrecogin alfa. European Medicines Agency schedules Drotrecogin alfa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20025.

The term Drotrecogin alfa is an International Non-Proprietary Name or INN ( see WHO INN reference publication, Volume 16., No. 1.2002, List 47). Most nations schedule Drotrecogin alfa under HS 30021095 and SITC 54163. SMILES:.

UNSPSC 51131661 Drotrecogin alfa is a Commodity code that nominally identifies a specific pharmaceutical product (a recombinant protein for sepsis treatment), but the single recent state and local opportunity tagged under this code shows a substantial mismatch with the code's intended scope. Sourcewell, a Minnesota local government unit and service cooperative, posted RFP #061626 on May 12, 2026 with a June 16, 2026 response deadline to establish a statewide contracting vehicle for law enforcement equipment — a procurement wholly unrelated to pharmaceutical procurement or drotrecogin alfa. The solicitation is available exclusively through the Sourcewell Procurement Portal and is open to vendors seeking to supply equipment to participating entities across Franklin, Grant, Grays Harbor, Chelan, and Yakima Counties in Washington, along with thousands of governmental agencies, higher education institutions, K-12 school districts, nonprofit organizations, tribal governments, and public entities throughout the United States and Canada.

The code shows minimal relevant recent activity for its intended pharmaceutical scope. The law enforcement equipment opportunity under RFP #061626 appears to be a tagging error rather than a legitimate procurement signal for drotrecogin alfa or related pharmaceutical products. No other state or local opportunities for this specific pharmaceutical appear in the recent record, and no issuing body, geographic concentration, or pattern of actual demand for the drug under this code is evident from available sources. Business development professionals should treat this code as inactive for practical state and local procurement purposes unless subsequent postings demonstrate that the tagging anomaly was resolved and legitimate pharmaceutical procurement activity begins to appear.